MCID: HYP014
MIFTS: 55

Hyperuricemia

Categories: Blood diseases, Metabolic diseases

Aliases & Classifications for Hyperuricemia

MalaCards integrated aliases for Hyperuricemia:

Name: Hyperuricemia 12 77 56 45 15 17 74
Blood Urate Raized 12
Uricacidemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1920
MeSH 45 D033461
NCIt 51 C3961
SNOMED-CT 69 35885006
UMLS 74 C0740394

Summaries for Hyperuricemia

Disease Ontology : 12 An acquired metabolic disease that has material basis in an abnormally high level of uric acid in the blood.

MalaCards based summary : Hyperuricemia, also known as blood urate raized, is related to hyperuricemic nephropathy, familial juvenile, 1 and glycogen storage disease ia, and has symptoms including seizures, muscle weakness and fever. An important gene associated with Hyperuricemia is UMOD (Uromodulin), and among its related pathways/superpathways are Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds and Thiopurine Pathway, Pharmacokinetics/Pharmacodynamics. The drugs Allopurinol and Furosemide have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and liver, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 77 Hyperuricemia is an abnormally high level of uric acid in the blood. In the pH conditions of body fluid,... more...

Related Diseases for Hyperuricemia

Diseases related to Hyperuricemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 213)
# Related Disease Score Top Affiliating Genes
1 hyperuricemic nephropathy, familial juvenile, 1 32.7 HPRT1 SLC22A12 UMOD
2 glycogen storage disease ia 32.5 G6PC INS
3 gout 31.3 ABCG2 HPRT1 SLC17A1 SLC17A3 SLC22A12 SLC2A9
4 chronic kidney failure 30.4 APOB INS REN UMOD
5 nephrolithiasis, uric acid 30.1 HPRT1 XDH
6 arteries, anomalies of 29.9 APOB INS REN
7 hypertension, essential 29.7 ADRB3 APOB INS REN
8 nephrolithiasis 29.6 HPRT1 INS SLC22A12 SLC2A9 UMOD XDH
9 nonalcoholic steatohepatitis 29.6 GPT INS
10 cerebrovascular disease 29.2 APOB INS REN
11 vascular disease 29.2 APOB INS REN XDH
12 diabetes mellitus, noninsulin-dependent 29.1 ADRB3 APOB G6PC GPT INS
13 hyperuricemia, pulmonary hypertension, renal failure, and alkalosis syndrome 12.6
14 glomerulocystic kidney disease with hyperuricemia and isosthenuria 12.4
15 deafness hyperuricemia neurologic ataxia 12.1
16 hyperuricemia, infantile, with abnormal behavior and normal hypoxanthine guanine phosphoribosyltransferase 12.1
17 nephropathy familial with hyperuricemia 12.1
18 lesch-nyhan syndrome 12.0
19 hyperuricemic nephropathy, familial juvenile, 2 11.9
20 kelley-seegmiller syndrome 11.9
21 fructose intolerance, hereditary 11.3
22 glycogen storage disease ib 11.2
23 autosomal dominant tubulointerstitial kidney disease 11.2
24 autosomal dominant tubulointerstitial kidney disease, ren-related 11.1
25 uric acid concentration, serum, quantitative trait locus 1 11.0
26 urate oxidase, pseudogene 11.0
27 glycogen storage disease ic 11.0
28 osteodysplasia, familial, anderson type 11.0
29 phosphoribosylpyrophosphate synthetase superactivity 11.0
30 hyperuricemic nephropathy, familial juvenile, 4 11.0
31 familial primary hypomagnesemia with hypercalciuria and nephrocalcinosis 11.0
32 kidney disease 10.6
33 arthritis 10.5
34 leukemia 10.4
35 heart disease 10.4
36 rere-related disorders 10.4
37 atrial fibrillation 10.3
38 lymphoma 10.3
39 coronary heart disease 1 10.3
40 diabetes mellitus 10.3
41 fatty liver disease 10.3
42 liver disease 10.3
43 nonalcoholic fatty liver disease 10.3
44 purine-pyrimidine metabolic disorder 10.3 HPRT1 XDH
45 glycogen storage disease 10.3
46 adenine phosphoribosyltransferase deficiency 10.2 HPRT1 XDH
47 myocardial infarction 10.2
48 fanconi-bickel syndrome 10.2 G6PC INS
49 hypouricemia, renal, 1 10.2 HPRT1 SLC22A12 SLC2A9
50 coronary artery anomaly 10.2

Graphical network of the top 20 diseases related to Hyperuricemia:



Diseases related to Hyperuricemia

Symptoms & Phenotypes for Hyperuricemia

UMLS symptoms related to Hyperuricemia:


seizures, muscle weakness, fever, polydipsia, dyspnea, edema, cachexia, vertigo, headache, syncope, cyanosis, icterus, signs and symptoms, signs and symptoms, digestive, hot flushes

MGI Mouse Phenotypes related to Hyperuricemia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.07 ABCG2 ADRB3 G6PC HPRT1 INS PFKM
2 homeostasis/metabolism MP:0005376 10.03 ABCG2 ADRB3 APOB G6PC HPRT1 INS
3 growth/size/body region MP:0005378 10.02 ADRB3 APOB G6PC HPRT1 INS REN
4 adipose tissue MP:0005375 9.88 ABCG2 ADRB3 INS SLC2A9 UMOD XDH
5 immune system MP:0005387 9.81 ABCG2 APOB HPRT1 INS PFKM REN
6 liver/biliary system MP:0005370 9.43 ABCG2 APOB G6PC HPRT1 INS SLC2A9
7 renal/urinary system MP:0005367 9.28 ABCG2 G6PC HPRT1 INS REN SLC22A12

Drugs & Therapeutics for Hyperuricemia

Drugs for Hyperuricemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 183)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Allopurinol Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 315-30-0 2094
2
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
3
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
4
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
5
Rasburicase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 134774-45-1
6
Febuxostat Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 144060-53-7 134018
7
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
8
Norethindrone Approved Phase 4 68-22-4 6230
9
Polyestradiol phosphate Approved Phase 4 28014-46-2
10
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
11
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
12
Probenecid Approved, Investigational Phase 4,Phase 2 57-66-9 4911
13
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
14
Colchicine Approved Phase 4,Phase 2,Phase 1 64-86-8 2833 6167
15
Naproxen Approved, Vet_approved Phase 4 22204-53-1 156391 1302
16
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
17
Chlorthalidone Approved Phase 4,Phase 3 77-36-1 2732
18
leucovorin Approved Phase 4 58-05-9 143 6006
19
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 11953898
20
Methylcobalamin Approved, Experimental, Investigational Phase 4 13422-55-4
21
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
22
Canagliflozin Approved Phase 4 842133-18-0
23
Bumetanide Approved Phase 4 28395-03-1 2471
24
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
25
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 54670067 5785
26
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
27
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
28
Uric acid Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 69-93-2 1175
29
Rosemary Experimental Phase 4
30
Cobalamin Experimental Phase 4 13408-78-1 6857388
31 Antioxidants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
32 Antiprotozoal Agents Phase 4
33 Free Radical Scavengers Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
34 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35
Procyanidin Phase 4 4852-22-6 147299
36 Proanthocyanidin Phase 4
37 Anti-Infective Agents Phase 4,Phase 3,Phase 1
38 Anthocyanidin Phase 4,Not Applicable
39 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Antiparasitic Agents Phase 4
41 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
42 Antihypertensive Agents Phase 4,Phase 2,Phase 3,Not Applicable
43 Sodium Chloride Symporter Inhibitors Phase 4,Phase 3
44 Natriuretic Agents Phase 4,Phase 3
45 Sodium Potassium Chloride Symporter Inhibitors Phase 4
46 diuretics Phase 4,Phase 3
47 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3
48 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
49 Hormones Phase 4,Phase 2,Phase 3
50 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3

Interventional clinical trials:

(show top 50) (show all 170)
# Name Status NCT ID Phase Drugs
1 Investigation of the Atherogenic Effects of Uric Acid-modified in Endothelial Dysfunction and the the Preventional Mechanism by Anthocyanidines Unknown status NCT02797028 Phase 4 Allopurinol
2 Clinical Trial to Compare Effectiveness of Diuretics in Hemodialysis Patients With Residual Renal Function Unknown status NCT01977430 Phase 4 Hydrochlorothiazide and furosemide
3 Prednisone for Heart Failure Patients With Hyperuricemia Completed NCT00919243 Phase 4 prednisone;allopurinol
4 Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome Completed NCT00563771 Phase 4 Rasburicase
5 Zurig (Febuxostat) 40mg Efficacy and Safety Trial Completed NCT02600780 Phase 4 Febuxostat;Allopurinol
6 Rasburicase in Tumor Lysis Syndrome Completed NCT00302653 Phase 4 Rasburicase
7 Treatment of Hyperuricemia in Patients With Heart Failure Completed NCT00422318 Phase 4 Benzbromarone (drug)
8 Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome Completed NCT01654276 Phase 4 Febuxostat
9 Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy Completed NCT00230217 Phase 4 Rasburicase (SR29142)
10 Allopurinol in Chronic Heart Failure Completed NCT00997542 Phase 4 Allopurinol;Placebo
11 Reversal of an Unfavorable Effect of Hydrochlorothiazide Compared to Angiotensin Converting Enzyme Inhibitor on Serum Uric Acid and Oxypurines Levels by Estrogen-progestin Therapy in Hypertensive Postmenopausal Women. Completed NCT03921736 Phase 4 Perindopril;Hydrochlorothiazide;Estracomb TTS
12 Drug Interaction Study of Olmesartan in Healthy Chinese Volunteers Completed NCT01907373 Phase 4 olmesartan medoxomil;olmesartan medoxomil+probenecid
13 Allopurinol Outcome Study Completed NCT01391325 Phase 4 Allopurinol
14 Weight Loss Improves Renal Hemodynamics Completed NCT01356394 Phase 4
15 Fasturtec TLS Treatment / Prophylysis Completed NCT00651911 Phase 4 urate oxidase
16 Immune Molecular and Inflammatory Cytokines Dysfunction Analysis in Gout Patients With Different Urate Levels Completed NCT02060552 Phase 4 Diacerein;Colchicine;Febuxostat
17 Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout Completed NCT02500641 Phase 4 Febuxostat 80/120mg/day;Allopurinol 100 up to 600mg/day;Colchicine;Naproxen;Omeprazole
18 Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients Recruiting NCT03200210 Phase 4 Febuxostat;Placebo
19 Effect of Hyperuricaemia on Chronic Renal Disease Recruiting NCT03425708 Phase 4 20mg Febuxostat;40mg Febuxostat
20 The Intervention of Multi-vitamin With Minerals to Hyperuricemia Recruiting NCT03218709 Phase 4
21 Urate Lowering Therapies and Left Ventricular Diastolic Dysfunction Active, not recruiting NCT03534037 Phase 4 Febuxostat 40 mg;Benzbromarone 50mg
22 The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics Active, not recruiting NCT02956278 Phase 4 Allopurinol
23 Pharmacogenetics of SGLT2 Inhibitors Active, not recruiting NCT02462421 Phase 4 Canagliflozin
24 The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF) Enrolling by invitation NCT03336203 Phase 4 Febuxostat 80 MG Oral Tablet or Allopurinol 300 MG Oral Tablet
25 Allopurinol in Acute Coronary Syndrome Not yet recruiting NCT03745729 Phase 4 allopurinol sustained-release capsules;placebo capsules
26 Use of Bumetanide and Chlorthalidone in the Volume Overload of Patients With Terminal Chronic Kidney Disease Not yet recruiting NCT03923933 Phase 4 Chlorthalidone;Bumetanide
27 the Effect of Febuxostat on Coronary Plaque Volume in Patients With Chronic Stable Angina and Hyperuricemia Terminated NCT02279342 Phase 4 Febuxostat
28 Long-term Prednisone Use for End-stage Heart Failure Unknown status NCT02282683 Phase 2, Phase 3 prednisone
29 The Effects of Doxazosin and Nifedipine on Blood Pressure Variability and Uric Acid in Plasma in Hypertensive Patients Unknown status NCT02563405 Phase 2, Phase 3 Doxazosin;Nifedipine
30 Role of Allopurinol on Oxidative Stress and Mitochondrial Alterations in Skeletal Muscle of Diabetic Patients Unknown status NCT02533648 Phase 3 2 capsules of allopurinol 150 mg daily for 3 month;2 capsules of lactose daily for 3 month
31 Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout Completed NCT03372200 Phase 3 FYU-981;Febuxostat
32 Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout Completed NCT03100318 Phase 3 FYU-981;Benzbromarone
33 Prednisone for Heart Failure Patients With Hyperuricemia Completed NCT02129764 Phase 2, Phase 3 Prednisone;Allopurinol
34 Study of FYU-981 in Hyperuricemia With or Without Gout Completed NCT03006445 Phase 3 FYU-981
35 Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia Completed NCT00921375 Phase 3 TULY
36 Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome Completed NCT00230178 Phase 3 Rasburicase (SR29142);Allopurinol
37 Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma Completed NCT00199043 Phase 3 Allopurinol;Rasburicase
38 Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout Completed NCT00325195 Phase 3
39 Efficacy and Safety of Oral Febuxostat in Participants With Gout Completed NCT00430248 Phase 3 Febuxostat;Febuxostat;Allopurinol
40 UAB Center of Research Translation (CORT) Project 2: The Effects of Urate Lowing Therapy (ULT) in Inflammation, Endothelial Function, and Blood Pressure Completed NCT02038179 Phase 2, Phase 3 Allopurinol;Placebo
41 Uric Acid and Hypertension in African Americans Completed NCT00241839 Phase 3 Allopurinol;Placebo;Chlorthalidone;Potassium chloride
42 Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout Completed NCT01356498 Phase 3
43 Molecular and Clinical Effects of Green Tea and Fermented Papaya Preparation on Diabetes and Cardiovascular Diseases Completed NCT01248143 Phase 2, Phase 3
44 Effect of Febuxostat on Endothelial Dysfunction in Hemodialysis Patients. Completed NCT02866214 Phase 2, Phase 3 Febuxostat;Placebo
45 Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010 Completed NCT00175019 Phase 3 Febuxostat;Febuxostat;Allopurinol
46 Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES) Completed NCT01101035 Phase 3 Febuxostat;Allopurinol
47 BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada Completed NCT00272779 Phase 3 ATV;RTV;Tenofovi-Emtricitabine (TDF/FTC) tablet;LPV
48 Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer Completed NCT01234337 Phase 3 Sorafenib (Nexavar, BAY43-9006);Placebo;Capecitabine
49 Rasburicase (Fasturtec) Registration Trial Terminated NCT00607152 Phase 3 Rasburicase;Allopurinol
50 Study of Levotofisopam 50 mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout Unknown status NCT01519687 Phase 2 levotofisopam

Search NIH Clinical Center for Hyperuricemia

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: hyperuricemia

Genetic Tests for Hyperuricemia

Anatomical Context for Hyperuricemia

MalaCards organs/tissues related to Hyperuricemia:

42
Kidney, Heart, Liver, Endothelial, Bone, Breast, Skeletal Muscle

Publications for Hyperuricemia

Articles related to Hyperuricemia:

(show top 50) (show all 1661)
# Title Authors Year
1
Coexistent Hyperuricemia and Gout in Rheumatoid Arthritis: Associations with Comorbidities, Disease Activity and Mortality. ( 31074584 )
2019
2
Inhibition of Hyperuricemia and Gouty Arthritis in BALB/c Mice Using Copper Oxide Nanoparticles. ( 31079329 )
2019
3
Editorial Commentary: Prevention and treatment of atrial fibrillation: Is hyperuricemia the next target? ( 30057151 )
2019
4
Hyperuricemia as an independent risk factor for non-alcoholic fatty liver disease (NAFLD) progression evaluated using controlled attenuation parameter-transient elastography: Lesson learnt from tertiary referral center. ( 30641737 )
2019
5
Treating hyperuricemia related non-alcoholic fatty liver disease in rats with resveratrol. ( 30557833 )
2019
6
Can hyperuricemia predict glycogen storage disease (McArdle's disease) in rheumatology practice? (Myogenic hyperuricemia). ( 31044384 )
2019
7
Functional Characterization of Clinically-Relevant Rare Variants in ABCG2 Identified in a Gout and Hyperuricemia Cohort. ( 31003562 )
2019
8
Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey 2007-2016. ( 30618180 )
2019
9
Achievement of Target Serum Uric Acid Levels and Factors Associated with Therapeutic Failure among Japanese Men Treated for Hyperuricemia/Gout. ( 30626825 )
2019
10
Common variants in the SLC28A2 gene are associated with serum uric acid level and hyperuricemia and gout in Han Chinese. ( 30679935 )
2019
11
Hyperuricemia and gout are associated with cancer incidence and mortality: A meta-analysis based on cohort studies. ( 30693505 )
2019
12
The Daniel K. Inouye College of Pharmacy Scripts: Perspectives on the Epidemiology of Gout and Hyperuricemia. ( 30766768 )
2019
13
Atypical musculoskeletal manifestations of gout in hyperuricemia patients. ( 30799962 )
2019
14
Hyperuricemia and acute gout after laparoscopic sleeve gastrectomy. ( 30815983 )
2019
15
Modified Chuanhu anti-gout mixture, a traditional Chinese medicine, protects against potassium oxonate-induced hyperuricemia and renal dysfunction in mice. ( 30832523 )
2019
16
The impact of dysfunctional variants of ABCG2 on hyperuricemia and gout in pediatric-onset patients. ( 30894219 )
2019
17
Associations of hyperuricemia, gout, and UA-lowering therapy with the risk of fractures: A meta-analysis of observational studies. ( 30910706 )
2019
18
Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. ( 29799677 )
2019
19
The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5. ( 30291473 )
2019
20
Crowned Dens Syndrome Associated with Hyperuricemia. ( 30333410 )
2019
21
Relation between prognostic impact of hyperuricemia and sympathetic overactivation in patients with heart failure. ( 30420104 )
2019
22
Association between hyperuricemia and nontraditional adiposity indices. ( 30498873 )
2019
23
Hyperuricemia and prognosis of acute ischemic stroke in diabetic patients. ( 30526444 )
2019
24
Implications of Hyperuricemia in Severe Coronary Artery Disease. ( 30527777 )
2019
25
Prevalence and risk factors associated with hyperuricemia among working population at high altitudes: a cross-sectional study in Western China. ( 30607652 )
2019
26
Hyperuricemia is associated with acute kidney injury and all-cause mortality in hospitalized patients. ( 30644622 )
2019
27
Hyperuricemia Predicts an Early Decline in Renal Function among Older People: A Community-Based Cohort Study. ( 30700753 )
2019
28
Prognostic value of hyperuricemia in patients with acute coronary syndrome: A meta-analysis. ( 30701529 )
2019
29
Exploration of Machine Learning for Hyperuricemia Prediction Models Based on Basic Health Checkup Tests. ( 30717373 )
2019
30
Hyperuricemia, urine uric excretion, and associated complications in thalassemia patients. ( 30721337 )
2019
31
Inhibiting PNP for the therapy of hyperuricemia in Lesch-Nyhan disease: Preliminary in vitro studies with analogues of immucillin-G. ( 30740729 )
2019
32
Long-term prognostic impact of hyperuricemia in community. ( 30777792 )
2019
33
Asymptomatic hyperuricemia and incident stroke in elderly Chinese patients without comorbidities. ( 30787471 )
2019
34
Beneficial Effect of Dietary Fiber on Hyperuricemia in Rats and Humans: A Review. ( 30789803 )
2019
35
Association between previous schistosome infection and incident hyperuricemia: A prospective cohort study in China. ( 30789970 )
2019
36
The Prevalence of Hyperuricemia Sharply Increases from the Late Menopausal Transition Stage in Middle-Aged Women. ( 30832319 )
2019
37
Hyperuricemia is Associated with Immunoglobulin G N-Glycosylation: A Community-Based Study of Glycan Biomarkers. ( 30835642 )
2019
38
Serum Uric Acid-Lowering Effects of Combined Glycine and Tryptophan Treatments in Subjects with Mild Hyperuricemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study. ( 30845731 )
2019
39
Lactobacillus brevis DM9218 ameliorates fructose-induced hyperuricemia through inosine degradation and manipulation of intestinal dysbiosis. ( 30852460 )
2019
40
Hyperuricemia and its related histopathological features on renal biopsy. ( 30885171 )
2019
41
Uricase and Horseradish Peroxidase Hybrid CaHPO₄ Nanoflower Integrated with Transcutaneous Patches for Treatment of Hyperuricemia. ( 30890227 )
2019
42
Flow-mediated dilation can be used to predict incident hypertension in patients with hyperuricemia. ( 30899286 )
2019
43
Conjugated Linoleic Acid Ameliorates High fructose-induced Hyperuricemia and Renal Inflammation in Rats via NLRP3 Inflammasome and TLR4 Signaling Pathway. ( 30913372 )
2019
44
Hypertriglyceridemia and hyperuricemia: a retrospective study of urban residents. ( 30935401 )
2019
45
Hepatocyte-Specific Ablation or Whole Body Inhibition of Xanthine Oxidoreductase in Mice Corrects Obesity-Induced Systemic Hyperuricemia Without Improving Metabolic Abnormalities. ( 30936145 )
2019
46
Gender- and Age-Specific Differences in the Association of Hyperuricemia and Hypertension: A Cross-Sectional Study. ( 30944567 )
2019
47
Changes of drug pharmacokinetics mediated by downregulation of kidney organic cation transporters Mate1 and Oct2 in a rat model of hyperuricemia. ( 30951542 )
2019
48
Hyperuricemia and Cardiovascular Disease. ( 30961478 )
2019
49
Maternal hyperuricemia superimposed on maternal hypertension aggravates the risk of small-for-gestational-age fetus. ( 31002916 )
2019
50
Association between SLC2A9 Genetic Variants and Risk of Hyperuricemia in a Uygur Population. ( 31016517 )
2019

Variations for Hyperuricemia

Expression for Hyperuricemia

Search GEO for disease gene expression data for Hyperuricemia.

Pathways for Hyperuricemia

GO Terms for Hyperuricemia

Cellular components related to Hyperuricemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apical plasma membrane GO:0016324 9.1 PFKM SLC17A1 SLC17A3 SLC22A12 SLC2A9 UMOD
2 endosome lumen GO:0031904 8.96 APOB INS

Biological processes related to Hyperuricemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 9.8 ABCG2 SLC17A1 SLC17A3 SLC22A12 SLC2A9
2 glucose homeostasis GO:0042593 9.61 G6PC INS PFKM
3 drug transmembrane transport GO:0006855 9.48 ABCG2 SLC17A3
4 glycogen catabolic process GO:0005980 9.37 G6PC PFKM
5 phosphate ion transport GO:0006817 9.32 SLC17A1 SLC17A3
6 sialic acid transport GO:0015739 9.26 SLC17A1 SLC17A3
7 urate transport GO:0015747 9.26 SLC17A1 SLC17A3 SLC22A12 SLC2A9
8 cholesterol efflux GO:0033344 9.16 APOB
9 glucose-6-phosphate transport GO:0015760 9.16 G6PC SLC17A3
10 urate metabolic process GO:0046415 9.1 ABCG2 G6PC SLC17A1 SLC17A3 SLC22A12 SLC2A9

Molecular functions related to Hyperuricemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.77 ABCG2 ADRB3 HPRT1 PFKM XDH
2 insulin-like growth factor receptor binding GO:0005159 9.26 INS REN
3 cholesterol transporter activity GO:0017127 9.02 APOB
4 sialic acid transmembrane transporter activity GO:0015136 8.96 SLC17A1 SLC17A3
5 drug transmembrane transporter activity GO:0015238 8.85 SLC17A3
6 urate transmembrane transporter activity GO:0015143 8.8 SLC17A3 SLC22A12 SLC2A9

Sources for Hyperuricemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....